Seamus Fernandez
Stock Analyst at Guggenheim
(3.64)
# 674
Out of 4,828 analysts
97
Total ratings
50%
Success rate
6.03%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $973 → $928 | $753.45 | +23.17% | 15 | Apr 14, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $11.25 | +291.29% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $13.40 | - | 3 | Apr 3, 2025 | |
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $4.28 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $31.81 | +402.99% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $24.03 | +133.09% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $14.79 | - | 2 | Feb 24, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $37.42 | - | 7 | Feb 10, 2025 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $33 | $19.04 | +73.32% | 1 | Nov 8, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $77.41 | +67.94% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $36.96 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $58.68 | +19.29% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.69 | +181.20% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.87 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.61 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $11.11 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $26.04 | +92.01% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.97 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $66.46 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $109.75 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.91 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.33 | +3,975.47% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $18.58 | +142.20% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $68.30 | -44.36% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $22.45 | +69.30% | 3 | Jan 31, 2018 |
Eli Lilly and Company
Apr 14, 2025
Maintains: Buy
Price Target: $973 → $928
Current: $753.45
Upside: +23.17%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $11.25
Upside: +291.29%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.40
Upside: -
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $4.28
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $31.81
Upside: +402.99%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $24.03
Upside: +133.09%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.79
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $37.42
Upside: -
Cidara Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $33
Current: $19.04
Upside: +73.32%
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $77.41
Upside: +67.94%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $36.96
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $58.68
Upside: +19.29%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.69
Upside: +181.20%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.61
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $11.11
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $26.04
Upside: +92.01%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $46.97
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $66.46
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $109.75
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.91
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.33
Upside: +3,975.47%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $18.58
Upside: +142.20%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $68.30
Upside: -44.36%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $22.45
Upside: +69.30%